Ischemic preconditioning reduces infarct size in patients treated with primary angioplasty

Original title: Preinfarction Angina Reduces Infarct Size in ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention Reference: Ronald Reiter et al. Circ Cardiovasc Interv. 2013;6:00-00.

Ischemic preconditioning (IPC) is a phenomenon whereby transitory ischemia episodes protect the myocardium against a more prolonged episode. 

Until now, IPC has been the most effective approach to protect the myocardium. Pre infarction angina is a clinical surrogate of IPC and has been associated with reduced infarct size in patients that receive thrombolytic therapy; however this is not conclusive for patients treated with primary angioplasty.

245 patients with ST elevation myocardial infarction treated with primary angioplasty were analyzed; 79 of these patients had presented angina 24 hours before admition vs. 166 patients without pre infarction angina. There were no significant differences in the rest of baseline characteristics between both groups.

For the patients with previous angina, both infarct size and troponin peak was significantly reduced (p<0,0001) despite having identical ischemic times and angiographic results. Ejection Fraction was 4$ lower in patients with preconditioning (51,4±1,1% vs. 47,5±1%; p=0,02).

Conclusion 

This study is the most detailed analysis carried out so far on the potential protective effect of ischemic preconditioning in patients with ST elevation myocardial infarction treated with primary angioplasty.

Editorial Comment

Randomized studies on ST elevation acute coronary syndromes should start considering pre infarction angina among key variables, seeing that this could be an important confounder, mainly if infarct size is one of the primary concerns. A good example of this is the large number of trials assessing the use of thrombi aspiration.

SOLACI.ORG

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....